Bath & Body Works (NYSE:BBWI – Get Free Report) issued an update on its first quarter earnings guidance on Tuesday morning. The company provided earnings per share guidance of $0.36-0.43 for the period, compared to the consensus earnings per share estimate of $0.42. Bath & Body Works also updated its FY26 guidance to $3.25-360 EPS.
Bath & Body Works Trading Down 6.6 %
BBWI stock opened at $30.45 on Tuesday. Bath & Body Works has a one year low of $26.20 and a one year high of $52.99. The firm has a 50-day moving average of $37.09 and a two-hundred day moving average of $34.14. The firm has a market capitalization of $6.60 billion, a PE ratio of 7.43, a P/E/G ratio of 0.92 and a beta of 1.89.
Bath & Body Works (NYSE:BBWI – Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported $2.09 EPS for the quarter, beating the consensus estimate of $2.04 by $0.05. Bath & Body Works had a net margin of 12.43% and a negative return on equity of 44.03%. The business had revenue of $2.79 billion during the quarter, compared to the consensus estimate of $2.78 billion. On average, equities research analysts anticipate that Bath & Body Works will post 3.3 earnings per share for the current year.
Bath & Body Works Dividend Announcement
Bath & Body Works declared that its Board of Directors has authorized a share repurchase plan on Thursday, February 27th that allows the company to repurchase $500.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.
Analysts Set New Price Targets
BBWI has been the subject of several research reports. Morgan Stanley decreased their price target on shares of Bath & Body Works from $51.00 to $48.00 and set an “overweight” rating for the company in a report on Thursday, November 21st. Citigroup raised shares of Bath & Body Works from a “neutral” rating to a “buy” rating and lifted their target price for the company from $40.00 to $48.00 in a research note on Friday, February 28th. JPMorgan Chase & Co. set a $47.00 price target on shares of Bath & Body Works in a research note on Thursday, February 27th. Cowen reiterated a “buy” rating on shares of Bath & Body Works in a report on Thursday, February 27th. Finally, Robert W. Baird boosted their target price on Bath & Body Works from $45.00 to $47.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $45.06.
Check Out Our Latest Research Report on Bath & Body Works
About Bath & Body Works
Bath & Body Works, Inc is a specialty retailers and home to America’s Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.
See Also
- Five stocks we like better than Bath & Body Works
- Health Care Stocks Explained: Why You Might Want to Invest
- Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
- 3 Monster Growth Stocks to Buy Now
- Walgreens Boots Alliance: Don’t Write Off This Asset Champ Yet
- Transportation Stocks Investing
- 5 ETFs Poised to Spring Ahead in the Second Quarter
Receive News & Ratings for Bath & Body Works Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bath & Body Works and related companies with MarketBeat.com's FREE daily email newsletter.